Back to Search
Start Over
Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies.
- Source :
-
EBioMedicine [EBioMedicine] 2021 Jul; Vol. 69, pp. 103427. Date of Electronic Publication: 2021 Jun 20. - Publication Year :
- 2021
-
Abstract
- Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction and is a primary cause of disability worldwide. Despite the existence of numerous anti-rheumatic drugs, a significant number of patients with RA do not respond or are intolerant to current treatments. Mesenchymal stem/stromal cell (MSCs) therapy represents a promising therapeutic tool to treat RA, mainly attributable to the immunomodulatory effects of these cells. This review comprises a comprehensive analysis of the scientific literature related to preclinical studies of MSC-based therapy in RA to analyse key aspects of current protocols as well as novel approaches which aim to improve the efficacy of MSC-based therapy.<br />Competing Interests: Declaration of Competing Interest None.<br /> (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2352-3964
- Volume :
- 69
- Database :
- MEDLINE
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- 34161884
- Full Text :
- https://doi.org/10.1016/j.ebiom.2021.103427